

## Peer Review File

Article information: <https://dx.doi.org/10.21037/med-23-48>

### Reviewer A

This is a concise and informative review on current knowledge of molecular alterations and targeted therapy in thymic carcinomas.

*R: We appreciate the deep understanding and supportive comments and suggestions from reviewer A.*

1. page 2, line 34: ....in the general transcription factor Iii (GTF2I). It should read ....factor Iii (GTF2I)

*R1: We thank reviewer A for pointing this out. We have changed "general transcription factor Iii (GTF2I)" to "general transcription factor Iii (GTF2I)" (page 3, lines 14-15).*

2. page 3, line 40: I suppose the plural form should be used - "receptor tyrosine kinases"

*R2: We thank reviewer A for pointing this out. According to the comment, we have changed "receptor tyrosine kinase" to "receptor tyrosine kinases" (page 4, line 31).*

3. page 5, line 38: ...inhibitor of VEGFR, FGFR, c-Kit, and... Maybe, better use KIT instead of c-kit throughout the manuscript. KIT is the "official" gene name.

*R3: We thank reviewer A for the important suggestion. The reviewer A is certainly correct. We have used KIT instead of c-Kit throughout the manuscript.*

4. page 6, line 14: ...PDGF-A and-B, and the stem cell factor receptor (72). The stem cell factor receptor is KIT. It would be helpful for the reader to put KIT in brackets or replace stem cell factor receptor with KIT.

*R4: We thank reviewer A for the important comment. We have replaced the stem cell factor receptor with KIT (page 8, line 13).*

### Reviewer B

This review seems comprehensive and is well written.

*R: We appreciate the deep understanding and supportive comments from reviewer B.*

### Reviewer C

Although this reviewer is unfamiliar with the format of a narrative review, this is a valuable overview of the most important molecular data and clinical trials dedicated to thymic carcinomas. I have missed a couple of references, but this may be due to the criteria imposed by the review

format. There was another phase II trial using octreotide in TET which the authors might want to cite (PMID: 27992479).

Otherwise, I have no substantial comments.

*R: We appreciate the deep understanding and supportive comments and suggestions from reviewer C. We have cited the suggested reference which we had missed, and had added some data on octreotide treatment for thymic carcinoma in the Targeted therapy in thymic carcinoma section (page 9, lines 13-16).*